scholarly journals Immunoblastic lymphadenopathy-like T cell lymphoma with high level of serum Interleukin-2 and various allergic reactions.

2002 ◽  
Vol 25 (6) ◽  
pp. 452-457 ◽  
Author(s):  
Masayuki Tsujisaki ◽  
Seiya Nakahara ◽  
Yoshie Kazama ◽  
Haruo Shimizu ◽  
Mitsuru Yoshimoto ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Interleukin 2 ◽  
T Cell Lymphoma ◽  
Allergic Reactions ◽  
High Level ◽  
Immunoblastic Lymphadenopathy

Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma

2015 ◽  
Vol 56 (9) ◽  
pp. 2592-2597 ◽  
Author(s):  
Souichi Shiratori ◽  
Mizuha Kosugi-Kanaya ◽  
Akio Shigematsu ◽  
Hajime Kobayashi ◽  
Satoshi Yamamoto ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Interleukin 2 ◽  
T Cell Lymphoma ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
Interleukin 2 Receptor ◽  
Poor Outcome ◽  
Soluble Interleukin 2 Receptor ◽  
High Level

Pancreatic T-cell lymphoma with high level of soluble interleukin-2 receptor

2002 ◽  
Vol 37 (10) ◽  
pp. 863-867 ◽  
Author(s):  
Hiroyuki Matsubayashi ◽  
Shinichi Takagaki ◽  
Takao Otsubo ◽  
Takao Iiri ◽  
Yuka Kobayashi ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Interleukin 2 ◽  
T Cell Lymphoma ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor ◽  
High Level

Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma

1998 ◽  
Vol 38 (2) ◽  
pp. 207-220 ◽  
Author(s):  
Eric C. Vonderheid ◽  
Qian Zhang ◽  
Stuart R. Lessin ◽  
Marcia Polansky ◽  
J.Todd Abrams ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Interleukin 2 ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

scholarly journals Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

Blood ◽  
2008 ◽  
Vol 111 (9) ◽  
pp. 4463-4470 ◽  
Author(s):  
Nathalie Mourad ◽  
Nicolas Mounier ◽  
Josette Brière ◽  
Emmanuel Raffoux ◽  
Alain Delmer ◽  
...  
Keyword(s):  
T Cell ◽  
Randomized Clinical Trials ◽  
Cell Lymphoma ◽  
Prognostic Significance ◽  
Lymphoid Cells ◽  
T Cell Lymphoma ◽  
Mediastinal Lymphadenopathy ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
Pathologic Features ◽  
High Level

AbstractTo evaluate the prognostic significance of clinicobiologic and pathological features in angioimmunoblastic T-cell lymphoma (AITL), 157 AITL patients were retrieved from the GELA LNH87-LNH93 randomized clinical trials. One hundred forty-seven patients received a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)–like regimen with intensified courses in half of them. Histologically, 41 cases were classified as “rich in large cells” and 116 as “classic” (including 19 rich in epithelioid cells, 14 rich in clear cells, and 4 with hyperplastic germinal centers). Sixty-two cases were scored for CD10 and CXCL13 expression according to the abundance of positive lymphoid cells. Median age was 62 years, with 81% advanced stage, 72% B symptoms, 65% anemia, 50% hypergammaglobulinemia, and 66% elevated LDH. Overall 7-year survival was 30%. In multivariate analysis, only male sex (P = .004), mediastinal lymphadenopathy (P = .041), and anemia (P = .042) adversely affected overall survival. Increase in large cells and high level of CD10 and CXCL13 did not affect survival. Intensive regimen did not improve survival. In conclusion, AITL is a morphologically heterogeneous T-cell lymphoma commonly expressing CXCL13 and CD10 and carrying few prognostic factors. It portends a poor prognosis even when treated intensively. However, AITL is not always lethal with 30% of patients alive at 7 years.

scholarly journals The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jin Hyun Kang ◽  
Seung Ho Lee ◽  
Jawon Lee ◽  
Murim Choi ◽  
Junhun Cho ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
T Cell ◽  
Cell Lymphoma ◽  
S100 Protein ◽  
Interleukin 2 ◽  
Ectopic Expression ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Lymphoma Patient ◽  
Akt Phosphorylation

Abstract Background BCOR acts as a corepressor of BCL6, a potent oncogenic protein in cancers of the lymphoid lineage. We have found the recurrent somatic mutation of BCOR occurred in mature T-cell lymphoma (TCL). The role of BCOR mutation in lymphoid malignancies is unknown. Methods Lymphoma patient samples were analyzed to identify missense mutations in BCOR using Sanger sequencing. Transfection, RNA interference, immunoprecipitation, western blotting, cell proliferation, cytokine assays and quantitative real-time PCR were employed to determine the functional relevance of the novel K607E mutation in BCOR. The significant transcriptional changes were analyzed by performing DNA microarray profiling in cells expressing BCOR K607E mutant. Results One hundred thirty-seven lymphoma patient samples were analyzed to identify K607E mutation of the BCOR gene. The BCOR K607E mutation was identified in 15 of 47 NK/T cell lymphoma cases (31.9%), 2 of 18 angioimmunoblastic T-cell lymphoma cases (11.1%), 10 of 30 peripheral T-cell lymphoma, not otherwise specified cases (33.3%), and 13 of 42 diffuse large B-cell lymphoma cases (30.9%). Molecular analysis of BCOR K607E mutation revealed that compared to the wild-type BCOR, the mutant BCOR bound to the BCL6, PCGF1, and RING1B proteins with lesser affinity. Ectopic expression of BCOR K607E mutant significantly enhanced cell proliferation, AKT phosphorylation and the expression of interleukin-2 (IL-2) with up-regulated expression of HOX and S100 protein genes in T cells. BCOR silencing also significantly enhanced cell proliferation, AKT phosphorylation, and IL-2 production. Conclusions Functional analyses indicated that K607E mutation of BCOR is oncogenic in nature and can serve as a genetic marker of T-cell lymphoma.

Successful Treatment of Immunoblastic Lymphadenopathy-Like T-cell Lymphoma with Cyclosporin A

1999 ◽  
Vol 35 (3-4) ◽  
pp. 389-395 ◽  
Author(s):  
Nobuo Takemori ◽  
Junichi Kodaira ◽  
Nobuyasu Toyoshima ◽  
Teiko Sato ◽  
Hiroharu Sakurai ◽  
...  
Keyword(s):  
T Cell ◽  
Cyclosporin A ◽  
Successful Treatment ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Immunoblastic Lymphadenopathy
Sign in / Sign up

Export Citation Format

Share Document